Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
AveXis, Inc. (AVXS) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/03/2018 GN AveXis Reports First Quarter 2018 Financial and Operating Results
05/01/2018 GN AveXis Provides Update on Proposed Acquisition by Novartis AG
04/08/2018 GN AveXis Enters Agreement to be Acquired by Novartis AG for $8.7 billion
03/27/2018 GN AveXis Gene Therapy Awarded SAKIGAKE Designation for Spinal Muscular Atrophy Type 1
03/14/2018 GN Report: Developing Opportunities within AveXis, LivaNova, FRP, Ross Stores, R1 RCM, and Criteo S.A — Future Expectations, Projections Moving into 2018
02/27/2018 GN AveXis Reports Fourth Quarter and Full Year 2017 Financial and Operating Results
02/20/2018 GN AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
01/30/2018 GN AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
01/22/2018 GN AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
01/16/2018 GN AveXis Announces Pricing of Public Offering of Common Stock
01/16/2018 GN AveXis Announces Proposed Public Offering of Common Stock
01/16/2018 GN AveXis Announces Expanded Clinical Development Program for AVXS-101 in Spinal Muscular Atrophy
12/13/2017 GN AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101
09/29/2017 GN AveXis Announces Plan to Initiate Pivotal Trial of AVXS-101 in SMA Type 1 Using Product from New GMP Commercial Process
08/10/2017 GN AveXis Reports Second Quarter 2017 Financial and Operating Results
06/26/2017 GN AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
06/20/2017 GN AveXis Announces Pricing of Public Offering of Common Stock
06/14/2017 GN AveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101
06/07/2017 GN REGENXBIO and AveXis Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
06/07/2017 GN AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
06/07/2017 GN AveXis and REGENXBIO Announce New Exclusive Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
04/25/2017 GN AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
03/16/2017 GN AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results
02/15/2017 GN AveXis Appoints Rick Modi as Senior Vice President and Chief Business Officer
02/06/2017 GN AveXis Announces Single-Arm Design for European Pivotal Study of AVXS-101 in SMA Type 1 Patients

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy